Alpha Flow
DVN Bulls Pay $5.8M for $50 by July as Biotech Call-Buying Surges
Friday, May 08, 2026 | Alpha Pod
Executive Summary
DVN call-buyers paid $5.8M for $50 strikes (Jul 17) across 67,762 contracts — the session’s cleanest directional bet, needing ~9.5% upside from $45.67 with a reverse collar underneath funding the position. MRNA followed with $11.4M deployed in $50 calls (Jul 17), structured with bullish bias, needing only a 2% push from $49.04 to clear the strike — a multi-month thesis well ahead of August earnings. CDE ran a Dec 18 risk reversal targeting 114% upside from $18.67, selling $12.50 puts to buy $40 calls. ZBRA saw aggressive pre-earnings call-buying — $1.8M into $220 calls (May 15) expiring the same week as Tuesday’s report.
Biotech/Pharma was the session’s clear thematic outlier at 69% bull, driven by genuine call-buying in LLY ($10.6M in $1100 calls, Jun 2027) and MRNA rather than background overwriting. Oil & Gas at 66% was pulled higher by DVN’s single-name conviction, though XLE and XOM both saw call-selling — a name-vs.-sector divergence. The remaining sectors clustered tightly between 53% and 65% on background overwriting with no actionable signal. Utilities was weakest at 53% on VST put-buying and GEV/OKLO call-selling.
SPY closed at $731.58 with aggregate flow mixed — 43% bull, 57% bear on $374M in premium. The dominant trade: 34.3K $740 calls (May 29), $27.8M deployed with bullish bias, targeting a 1.2% push above spot. Opposing that: a 53.6K $710/$675 put spread (May 29), ~$15.2M net debit, positioning for a move below $710. SPX institutional flow sold calls at the same $740 SPY-equivalent strike, creating a contested ceiling. Macro-scale SPX structured flow was massive — a Sep 18 collar and Feb 2027 bullish framing dominated, with $309M in $8000 puts (Sep 18) as deep tail hedging.
